2156634-62-5

2156634-62-5 structure

2156634-62-5 structure

Name: Befovacimab
Chemical Name: Befovacimab
CAS Number: 2156634-62-5
Molecular Formula:
Molecular Weight:
Catalog: Signaling Pathways Metabolic Enzyme/Protease Thrombin
Create Date: 2023-01-15 16:26:06
Modify Date: 2024-01-10 17:52:38
Befovacimab (BAY 1093884) is a fully human monoclonal IgG2 antibody able to bind to tissue factor pathway inhibitor (TFPI). Befovacimab can be used for haemophilia A/B research[1].

Name	Befovacimab

Description	Befovacimab (BAY 1093884) is a fully human monoclonal IgG2 antibody able to bind to tissue factor pathway inhibitor (TFPI). Befovacimab can be used for haemophilia A/B research[1].
Related Catalog	Research Areas >> Cardiovascular Disease Signaling Pathways >> Metabolic Enzyme/Protease >> Thrombin
In Vitro	Befovacimab 通过 K1 和 K2 结构域以高亲和力 (<10 pM) 结合人 TFPI，抑制其与 FXa 和 FVIIa 的相互作用，从而恢复它们的活性[1]。
In Vivo	在猴血浆中，Befovacimab 对游离 TFPI 和稀释的凝血酶原时间 (dPT) 的 IC50 分别为 4.65 nM 和 6.19 nM[1]。 Befovacimab（5 和 20 mg/kg；静脉和皮下给药）剂量依赖性降低体内雌性食蟹猴的 TFPI 浓度和凝血时间[1]。
References	[1]. Maria Elisa Mancuso, et al. Befovacimab, an anti-tissue factor pathway inhibitor antibody: Early termination of the multiple-dose, dose-escalating Phase 2 study due to thrombosis. Haemophilia. 2022 Sep;28(5):702-712. [2]. Jian-Ming Gu, et al. Mechanistic Modeling of the Pharmacodynamic and Pharmacokinetic Relationship of Tissue Factor Pathway Inhibitor-Neutralizing Antibody (BAY 1093884) in Cynomolgus Monkeys. AAPS J. 2017 Jul;19(4):1186-1195.

No Any Chemical & Physical Properties